Moderna (NASDAQ:MRNA) Issues Earnings Results

Moderna (NASDAQ:MRNA) announced its quarterly earnings results on Thursday. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92, Briefing.com reports. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same quarter in the prior year, the company posted ($1.39) EPS. The company’s quarterly revenue was up 3.8% on a year-over-year basis.

Moderna Stock Performance

MRNA traded down $3.45 during trading hours on Friday, hitting $46.83. 13,561,538 shares of the stock were exchanged, compared to its average volume of 4,882,079. The stock has a 50-day simple moving average of $61.85 and a 200-day simple moving average of $99.22. Moderna has a 12 month low of $46.57 and a 12 month high of $170.47. The stock has a market cap of $18.00 billion, a price-to-earnings ratio of -3.04 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.92.

Analyst Ratings Changes

Several equities analysts have recently commented on MRNA shares. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and decreased their price target for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Piper Sandler decreased their price target on Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Friday. The Goldman Sachs Group cut their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Finally, Barclays cut their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $93.18.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,184 shares of company stock worth $238,531 over the last ninety days. 15.70% of the stock is owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.